Gettman v. Drug Enforcement Administration

290 F.3d 430, 351 U.S. App. D.C. 344, 2002 U.S. App. LEXIS 9836, 2002 WL 1040572
CourtCourt of Appeals for the D.C. Circuit
DecidedMay 24, 2002
Docket01-1182
StatusPublished
Cited by72 cases

This text of 290 F.3d 430 (Gettman v. Drug Enforcement Administration) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gettman v. Drug Enforcement Administration, 290 F.3d 430, 351 U.S. App. D.C. 344, 2002 U.S. App. LEXIS 9836, 2002 WL 1040572 (D.C. Cir. 2002).

Opinion

Opinion for the Court filed by Circuit Judge SENTELLE.

SENTELLE, Circuit Judge:

Jon Gettman and High Times Magazine petition this Court for review of the March 20, 2001 decision of the Drug Enforcement Administration (“DEA”) denying their petition to initiate rulemaking proceedings to reschedule marijuana under 21 U.S.C. § 811(a). See Drug Enforcement Administration Notice of Denial of Petition, 66 Fed.Reg. 20038 (April 18, 2001). The DEA contends we should dismiss the petition for review, arguing that neither Gett-man nor High Times Magazine has standing to bring this petition. Because we agree with the DEA, we dismiss the petition.

*432 I. Background

The Controlled Substances Act, 21 U.S.C. § 801, et seq., sets forth initial schedules of drugs and controlled substances in 21 U.S.C. § 812(c). However, Congress established procedures for adding or removing substances from the schedules (control or decontrol), or to transfer a drug or substance between schedules (reschedule). 21 U.S.C. § 811(a). This responsibility is assigned to the Attorney General in consultation with the Secretary of Health and Human Services (“HHS”). Id. § 811(b). The Attorney General has delegated his functions to the Administrator of the DEA. 28 C.F.R. § 0.100(b). Current schedules are published at 21 C.F.R. §§ 1308.11-1308.15.

There are three methods by which the DEA may initiate rulemaking proceedings to revise the schedules: (1) by the DEA’s own motion; (2) at the request of HHS; (3)on the petition of any interested party. 21 U.S.C. § 811(a); 21 C.F.R. § 1308.43(a). Before initiating rulemaking proceedings, the DEA must request a scientific and medical evaluation from HHS and a recommendation. The statute requires the DEA and HHS to consider eight factors with respect to the drug or controlled substance. 21 U.S.C. § 811(b), (c). These factors are:

(1) Its actual or relative potential for abuse.
(2) Scientific evidence of its pharmacological effect, if known.
(3) The state of current scientific knowledge regarding the drug or other substance.
(4) Its history and current pattern of abuse.
(5) The scope, duration, and significance of abuse.
(6) What, if any, risk there is to the public health.
(7) Its psychic or physiological dependence liability.
(8) Whether the substance is an immediate precursor of a substance already controlled under this subchapter.

21 U.S.C. § 811(c). Although the recommendations of HHS are binding on the DEA as to scientific and medical considerations involved in the eight-factor test, the ultimate decision as to whether to initiate rulemaking proceedings to reschedule a controlled substance is made by the DEA. See id. § 811(a), (b).

Jon Gettman petitioned the DEA in 1995 to initiate rulemaking proceedings under 21 U.S.C. § 811(a) to reschedule various controlled substances, including marijuana. Subsequently High Times Magazine joined with him as a petitioner. In their petition to DEA, Gettman and High Times claimed that “there is no scientific evidence that [marijuana has] sufficient abuse potential to warrant schedule I or II status” under the Controlled Substances Act. In accordance with 21 U.S.C. § 811(b), the DEA forwarded the petition to HHS in 1997. In 2001, HHS recommended that marijuana remain in schedule I and the DEA in turn denied the petition. No action has been taken regarding the other drugs initially named by Gettman.

Gettman and High Times filed this petition for review of the DEA’s refusal to initiate rulemaking proceedings to reschedule marijuana. On our own motion, we ordered supplemental briefing on standing, and specifically asked parties to address the issue of injury.

II. Analysis

Article III, section 2, clause 1 of the United States Constitution limits the “judicial power” of the United States to the resolution of “cases” or “controversies.” Valley Forge Christian College v. Americans United for Separation of *433 Church & State, Inc., 454 U.S. 464, 471, 102 S.Ct. 752, 757-58, 70 L.Ed.2d 700 (1982); see Chicago & Grand Trunk Ry. Co. v. Wellman, 143 U.S. 339, 345, 12 S.Ct. 400, 402, 36 L.Ed. 176 (1892). In order to establish the existence of a case or controversy within the meaning of Article III, the party must meet certain constitutional minima. As relevant to this case, these include the requirement that the party must demonstrate that it has standing to bring the action. See Lujan v. Defenders of Wildlife, 504 U.S. 555, 560, 112 S.Ct. 2130, 2136, 119 L.Ed.2d 351 (1992). “Those who do not possess Art. Ill standing may not litigate as suitors in the courts of the United States.” Valley Forge, 454 U.S. at 475-76, 102 S.Ct. at 760. Petitioners seem to believe that their “commitment” to their cause and the alleged importance of their cause is enough to confer Article III standing. It is not. Sierra Club v. Motion, 405 U.S. 727, 739, 92 S.Ct. 1361, 1368, 31 L.Ed.2d 636 (1972). To satisfy the constitutional requirement of standing, a plaintiff or petitioner must, at an “irreducible constitutional minimum ... demonstrate that it has suffered a concrete and particularized injury that is: (1) actual or imminent, (2) caused by, or fairly traceable to an act that the litigant challenges in the instant litigation, and (3) redressable by the court.” Florida Audubon Soc’y v. Bentsen,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

US Inventor, Inc. v. PTO
Federal Circuit, 2025
Robertson v. District of Columbia
District of Columbia, 2025
Viasat, Inc. v. FCC
D.C. Circuit, 2022
Sierra Club v. Perry
District of Columbia, 2019
Sierra Club v. Perry
373 F. Supp. 3d 128 (D.C. Circuit, 2019)
Student Loan Servicing Alliance v. Dist. of Columbia
351 F. Supp. 3d 26 (D.C. Circuit, 2018)
SAI v. Transp. Sec. Admin.
315 F. Supp. 3d 218 (D.C. Circuit, 2018)
Sorenson Commc'ns, LLC v. Fed. Commc'ns Comm'n
897 F.3d 214 (D.C. Circuit, 2018)
Aarp v. United States Equal Employment Opportunity Commission
267 F. Supp. 3d 14 (District of Columbia, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
290 F.3d 430, 351 U.S. App. D.C. 344, 2002 U.S. App. LEXIS 9836, 2002 WL 1040572, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gettman-v-drug-enforcement-administration-cadc-2002.